Managing Nausea and Vomiting with Zepbound (Tirzepatide)
First-Line Antiemetic Treatment
- The American Gastroenterological Association recommends starting with a 5-HT3 receptor antagonist, such as ondansetron 4-8 mg twice or three times daily, as the primary antiemetic for managing nausea and vomiting in patients taking Zepbound 1
- The American Gastroenterological Association also suggests granisetron 1 mg twice daily or granisetron transdermal patch 34.3 mg weekly as alternative options for first-line antiemetic treatment in patients taking Zepbound 1
Second-Line Options if 5-HT3 Antagonists Fail
- The American Society of Clinical Oncology recommends metoclopramide 20-30 mg three to four times daily as a second-line option for managing nausea and vomiting in patients taking Zepbound, if 5-HT3 antagonists are insufficient 2, 1
- The American Society of Clinical Oncology also suggests prochlorperazine 5-10 mg four times daily as an alternative second-line option for managing nausea and vomiting in patients taking Zepbound, if 5-HT3 antagonists are insufficient 2, 1
Adjunctive Therapy for Breakthrough Symptoms
- The National Comprehensive Cancer Network recommends lorazepam 0.5-2 mg every 4-6 hours as needed, as an adjunctive therapy for breakthrough nausea and vomiting in patients taking Zepbound 3
- The National Comprehensive Cancer Network suggests considering around-the-clock dosing rather than PRN for continuous symptoms in patients taking Zepbound 3
Critical Safety Considerations
- The National Comprehensive Cancer Network recommends checking and correcting electrolytes if vomiting is severe in patients taking Zepbound 3
Additional Supportive Measures
- The National Comprehensive Cancer Network recommends ensuring adequate hydration, through oral or IV fluid repletion as needed, in patients taking Zepbound 3